MedTrace Logo

Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study

NCT07091214 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-07-29

No results posted yet for this study

Summary

Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years). Current biopsy-based diagnoses of rejection (using Banff 2022 criteria) suffer from variability and limited sensitivity. PANDA-Kids-ATLAS will analyze up to 600 pediatric FFPE kidney biopsies across multiple centres using the Banff Human Organ Transplant (B-HOT) NanoString panel to develop and validate molecular classifiers of AMR, TCMR and related phenotypes. A secure REDCap database will integrate molecular, pathological and clinical data, aiming to improve early detection, personalize therapy, and enhance long-term graft survival and patient quality of life.

Conditions

  • Kidney Rejection Transplant

Sponsors & Collaborators

  • Paris Cardiovascular Research Center (Inserm U970)

    collaborator OTHER_GOV

  • Paris Translational Research Center for Organ Transplantation

    lead OTHER

Principal Investigators

  • Evgenia Preka, MD, PhDc · INSERM U970

  • Alexandre Loupy, MD, PhD · INSERM U970

  • Valentin Goutaudier, MD, PhD · INSERM U970

Eligibility

Min Age
0 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07091214 on ClinicalTrials.gov